Neogenomics (NEO) Current Deferred Revenue (2017 - 2026)

Neogenomics (NEO) has 10 years of Current Deferred Revenue data on file, last reported at $528000.0 in Q2 2026.

• Quarterly Current Deferred Revenue fell 65.42% year-over-year to $528000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $528000.0 (down 65.42% YoY) and the FY2025 annual result came in at $1.2 million, up 66.04% from the prior year.
• Current Deferred Revenue slipped to $528000.0 in Q2 2026, from $899000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $7.6 million in Q4 2022 to a low of $528000.0 in Q2 2026.
• A 5-year average of $3.3 million and a median of $1.8 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue tumbled 81.14% — and 2025, when it surged 111.47%.
• Tracing NEO's Current Deferred Revenue over 5 years: stood at $7.6 million in 2022, then tumbled by 71.88% to $2.1 million in 2023, then slumped by 65.02% to $745000.0 in 2024, then jumped by 66.04% to $1.2 million in 2025, then plunged by 57.32% to $528000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $528000.0 (Q2 2026), $899000.0 (Q1 2026), and $1.2 million (Q4 2025), per Business Quant data.